DrugId:  1
1. Name:  Abiraterone
2. Groups:  Approved
3. Description:  Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
4. Indication:  Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer. 
DrugId:  2
1. Name:  Triamterene
2. Groups:  Approved
3. Description:  A pteridine that is used as a mild diuretic. [PubChem]
4. Indication:  For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism.
DrugId:  3
1. Name:  Potassium Chloride
2. Groups:  Approved, Withdrawn
3. Description:  A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.
4. Indication:  For use as an electrolyte replenisher and in the treatment of hypokalemia.
